MoneyWorks4Me

Everest Organics - Quaterly Results

09 Feb 2024 Evaluate
The Revenue for the quarter ended  December 2023 of Rs. 525.07 millions grew by 21.28 % from Rs. 432.94 millions.The company reported a drastic decline of -98.82% in the quarter ended December 2023 to Rs. 0.18  millions from Rs. 15.20 millions  .Operating profit for the quarter ended December 2023 decreased to 29.30 millions as compared to 31.59 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 525.07 432.94 21.28 1446.25 1322.94 9.32 1830.48 2000.47 -8.50
Other Income 1.30 56.49 -97.70 5.89 62.54 -90.58 69.44 22.11 214.07
PBIDT 29.30 31.59 -7.25 86.16 49.03 75.73 78.74 86.39 -8.86
Interest 14.47 8.14 77.76 42.24 23.57 79.21 33.10 31.03 6.67
PBDT 14.83 23.45 -36.76 43.92 25.46 72.51 45.64 55.36 -17.56
Depreciation 13.30 10.98 21.13 39.44 32.15 22.67 44.74 37.97 17.83
PBT 1.53 12.47 -87.73 4.48 -6.69 -166.97 0.90 17.39 -94.82
TAX 1.35 -2.73 -149.45 3.67 -3.73 -198.39 2.72 5.96 -54.36
Deferred Tax 1.15 -2.73 -142.12 2.97 -3.73 -179.62 2.57 3.06 -16.01
PAT 0.18 15.20 -98.82 0.81 -2.96 -127.36 -1.82 11.43 -115.92
Equity 80.00 80.00 0.00 80.00 80.00 0.00 80.00 80.00 0.00
PBIDTM(%) 5.58 7.30 -23.52 5.96 3.71 60.75 4.30 4.32 -0.39
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..